Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer

Rosario Vincenzo Iaffaioli, Anna Tortoriello, Gaetano Facchini, Michele Santangelo, Luigi Bucci, Landino Fei, Natale Di Martino, Giovanni Mantovani, Francesco Caponigro

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

44 patients with advanced breast cancer were treated with high-dose epirubicin (130 mg/sqm), because of its steep dose-response curve. Lonidamine and alpha interferon were administered as well with the aim of increasing epirubicin uptake and overcoming drug resistance. Granulocyte-colony stimulating factor support was provided. 14 complete responses and 22 partial responses were observed in 40 evaluable patients for a 90% overall response rate. Median duration of response was 12 months for complete responders, 7 months for partial responders. In two cases the complete response has lasted for more than two years. Myelosuppression, infection, and cardiac toxicity were the main treatment-related toxic effects. These results are encouraging enough to justify a randomized comparison of our chemotherapy program with standard regimens used in advanced breast cancer.

Original languageEnglish
Pages (from-to)243-248
Number of pages6
JournalBreast Cancer Research and Treatment
Volume35
Issue number3
DOIs
Publication statusPublished - Sep 1995

Fingerprint

interferon alfa-2b
Epirubicin
Breast Neoplasms
Poisons
Granulocyte Colony-Stimulating Factor
Drug Resistance
Interferon-alpha
Drug Therapy
Infection
lonidamine
Therapeutics

Keywords

  • advanced breast cancer
  • alpha interferon
  • epirubicin
  • high-dose chemotherapy
  • lonidamine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. / Iaffaioli, Rosario Vincenzo; Tortoriello, Anna; Facchini, Gaetano; Santangelo, Michele; Bucci, Luigi; Fei, Landino; Di Martino, Natale; Mantovani, Giovanni; Caponigro, Francesco.

In: Breast Cancer Research and Treatment, Vol. 35, No. 3, 09.1995, p. 243-248.

Research output: Contribution to journalArticle

Iaffaioli, RV, Tortoriello, A, Facchini, G, Santangelo, M, Bucci, L, Fei, L, Di Martino, N, Mantovani, G & Caponigro, F 1995, 'Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer', Breast Cancer Research and Treatment, vol. 35, no. 3, pp. 243-248. https://doi.org/10.1007/BF00665975
Iaffaioli, Rosario Vincenzo ; Tortoriello, Anna ; Facchini, Gaetano ; Santangelo, Michele ; Bucci, Luigi ; Fei, Landino ; Di Martino, Natale ; Mantovani, Giovanni ; Caponigro, Francesco. / Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. In: Breast Cancer Research and Treatment. 1995 ; Vol. 35, No. 3. pp. 243-248.
@article{7249431537114bc5903010f8f18c9c07,
title = "Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer",
abstract = "44 patients with advanced breast cancer were treated with high-dose epirubicin (130 mg/sqm), because of its steep dose-response curve. Lonidamine and alpha interferon were administered as well with the aim of increasing epirubicin uptake and overcoming drug resistance. Granulocyte-colony stimulating factor support was provided. 14 complete responses and 22 partial responses were observed in 40 evaluable patients for a 90{\%} overall response rate. Median duration of response was 12 months for complete responders, 7 months for partial responders. In two cases the complete response has lasted for more than two years. Myelosuppression, infection, and cardiac toxicity were the main treatment-related toxic effects. These results are encouraging enough to justify a randomized comparison of our chemotherapy program with standard regimens used in advanced breast cancer.",
keywords = "advanced breast cancer, alpha interferon, epirubicin, high-dose chemotherapy, lonidamine",
author = "Iaffaioli, {Rosario Vincenzo} and Anna Tortoriello and Gaetano Facchini and Michele Santangelo and Luigi Bucci and Landino Fei and {Di Martino}, Natale and Giovanni Mantovani and Francesco Caponigro",
year = "1995",
month = "9",
doi = "10.1007/BF00665975",
language = "English",
volume = "35",
pages = "243--248",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer

AU - Iaffaioli, Rosario Vincenzo

AU - Tortoriello, Anna

AU - Facchini, Gaetano

AU - Santangelo, Michele

AU - Bucci, Luigi

AU - Fei, Landino

AU - Di Martino, Natale

AU - Mantovani, Giovanni

AU - Caponigro, Francesco

PY - 1995/9

Y1 - 1995/9

N2 - 44 patients with advanced breast cancer were treated with high-dose epirubicin (130 mg/sqm), because of its steep dose-response curve. Lonidamine and alpha interferon were administered as well with the aim of increasing epirubicin uptake and overcoming drug resistance. Granulocyte-colony stimulating factor support was provided. 14 complete responses and 22 partial responses were observed in 40 evaluable patients for a 90% overall response rate. Median duration of response was 12 months for complete responders, 7 months for partial responders. In two cases the complete response has lasted for more than two years. Myelosuppression, infection, and cardiac toxicity were the main treatment-related toxic effects. These results are encouraging enough to justify a randomized comparison of our chemotherapy program with standard regimens used in advanced breast cancer.

AB - 44 patients with advanced breast cancer were treated with high-dose epirubicin (130 mg/sqm), because of its steep dose-response curve. Lonidamine and alpha interferon were administered as well with the aim of increasing epirubicin uptake and overcoming drug resistance. Granulocyte-colony stimulating factor support was provided. 14 complete responses and 22 partial responses were observed in 40 evaluable patients for a 90% overall response rate. Median duration of response was 12 months for complete responders, 7 months for partial responders. In two cases the complete response has lasted for more than two years. Myelosuppression, infection, and cardiac toxicity were the main treatment-related toxic effects. These results are encouraging enough to justify a randomized comparison of our chemotherapy program with standard regimens used in advanced breast cancer.

KW - advanced breast cancer

KW - alpha interferon

KW - epirubicin

KW - high-dose chemotherapy

KW - lonidamine

UR - http://www.scopus.com/inward/record.url?scp=0028999807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028999807&partnerID=8YFLogxK

U2 - 10.1007/BF00665975

DO - 10.1007/BF00665975

M3 - Article

VL - 35

SP - 243

EP - 248

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -